The California Collaborative Treatment Group (CCTG) is a clinical trials consortium of academic institutions and community-based organizations in Southern California.
Since 1986, the CCTG has conducted high-impact, multi-center, investigator-initiated clinical trials focusing on:
- HIV treatment and management
- Risk reduction behavioral interventions
- Pre-Exposure Prophylaxis (PrEP)
- The CCTG research team includes clinicians, psychologists, behavioral scientists, biostatisticians, and pharmacology experts.
The CCTG Administrative Core is located at the UCSD AVRC. Collaborators include:
Current funding for the CCTG is provided by the California HIV/AIDS Research Program (CHRP) and backed by the California State Legislature. CHRP fosters outstanding and innovative research that responds to the needs of all people of California, especially those who are often underserved, by accelerating progress in prevention, education, care, treatment, and a cure for HIV/AIDS.
Community members interested in participating in a CCTG study should contact the Screening Coordinator at (619) 543-8080.
Recent Publications and Results
|CCTG 600||Jill Blumenthal, MD et al||International Workshop on HIV & Women||PrEPing for a PrEP Demonstration Project: Understanding Awareness and Perspectives among Women in Southern California|
|CCTG 596||Kathleen Jacobson, MD et al||National HIV Prevention Conference||Best Practices for Incentivized Social Network Recruitment for HIV Case Finding|
|CCTG 595||Martin Hoenigl, MD et al||2017 Conference on Retroviruses and Opportunistic Infections||Substance-using MSM on HIV Pre-Exposure Prophylaxis Have Better Adherence|
|CCTG 595||Michael Dubé, MD et al||18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV||Tenofovir disoproxil fumarate associated with Fanconi syndrome in an HIV uninfected man receiving HIV pre-exposure prophylaxis|
|CCTG 595||David Moore, PhD et al||HIV Research for Prevention||Randomized Controlled Trial of Daily Text Messages for Adherence to Pre-Exposure Prophylaxis (PrEP) in Men who have Sex with Men and Transgender Women|
|CCTG 595||Jill Blumenthal, MD et al||International AIDS Society||Text messaging responses correlate with tenofovir-disphosphate dried blood spot concentrations among men who have sex with men on pre-exposure prophylaxis|
|CCTG 595||Joel Milam, PhD et al||International AIDS Society||Risk compensation among men who have sex with men (MSM) in Southern California following the initiation of pre-exposure prophylaxis (PrEP)|
|CCTG 595||Sheldon Morris, MD MPH et al||National Summit HCV and HIV Diagnosis, Prevention, and Access to Care||Comparison of behavioral factors in men who have sex with men who go on HIV pre-exposure prophylaxis by partner status|
|CCTG 595||Eric Ellorin, et al||Infectious Diseases Society of America||Barriers to Health Insurance Coverage and Intention to Continue Pre-Exposure Prophylaxis (PrEP) Reported by Men who have Sex with Men (MSM) in a PrEP Demonstration Project|